WO2009059188A1 - Method of treating vitamin b12 deficiency - Google Patents

Method of treating vitamin b12 deficiency Download PDF

Info

Publication number
WO2009059188A1
WO2009059188A1 PCT/US2008/082064 US2008082064W WO2009059188A1 WO 2009059188 A1 WO2009059188 A1 WO 2009059188A1 US 2008082064 W US2008082064 W US 2008082064W WO 2009059188 A1 WO2009059188 A1 WO 2009059188A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
pharmaceutical composition
snac
tablet
deficiency
Prior art date
Application number
PCT/US2008/082064
Other languages
French (fr)
Inventor
Cristina Castelli
Laura Kragie
Original Assignee
Emisphere Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009059188(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK08844673.7T priority Critical patent/DK2215047T3/en
Priority to CA2704780A priority patent/CA2704780C/en
Priority to AU2008318423A priority patent/AU2008318423B2/en
Priority to NZ585080A priority patent/NZ585080A/en
Priority to MX2010004716A priority patent/MX2010004716A/en
Priority to BRPI0817396A priority patent/BRPI0817396C8/en
Priority to PL08844673T priority patent/PL2215047T3/en
Application filed by Emisphere Technologies, Inc. filed Critical Emisphere Technologies, Inc.
Priority to EP08844673.7A priority patent/EP2215047B1/en
Priority to RU2010118423/15A priority patent/RU2469728C2/en
Priority to ES08844673.7T priority patent/ES2443817T3/en
Priority to CN200880119724.0A priority patent/CN101952241B/en
Priority to JP2010532292A priority patent/JP5555634B2/en
Publication of WO2009059188A1 publication Critical patent/WO2009059188A1/en
Priority to CL2010000434A priority patent/CL2010000434A1/en
Priority to HK11100634.9A priority patent/HK1146480A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates generally to methods of treating vitamin B 12 deficiency and pharmaceutical compositions for such treatment.
  • Vitamin B 12 is important for the normal functioning of the brain and nervous system and for the formation of blood. It is involved in the metabolism of every cell of the body, especially affecting the DNA synthesis and regulation but also fatty acid synthesis and energy production. Its effects are still not completely known.
  • Cyanocobalamin is the most stable and widely used form of vitamin Bu ⁇ ll is bound to plasma proteins and stored in the liver. Vitamin Bi 2 is excreted in the bile and undergoes some enterohepatic recycling. Absorbed vitamin Bi 2 is transported via specific Bj 2 binding proteins, transcobalamin I and II, to the various tissues. The liver is the main organ for vitamin B 12 storage.
  • Vitamin B] 2 deficiency can potentially cause severe and irreversible damage, especially to the brain and nervous system.
  • Oral tablets containing vitamin Bi 2 have been developed to treat vitamin Bj 2 deficiency.
  • many patients with vitamin B n deficiency do not respond to oral vitamin B 12 treatment. There is a need to develop a treatment for these patients.
  • One aspect of the invention is directed to a method for treating vitamin B [2 deficiency in a subject, comprising the steps of (a) preparing a pharmaceutical composition for oral administration containing (1) vitamin B] 2 and (2) at least one substance selected from the group consisting of /V-[8-(2 ⁇ hydroxybenzoyl) amino]caprylic acid and its pharmaceutically acceptable salts; and (b) administering the pharmaceutical composition to the subject to effectively treat said vitamin Bi 2 deficiency.
  • Another aspect of the invention is directed to a pharmaceutical composition for treating vitamin Bj 2 deficiency in a subject, comprising (1) vitamin B 12 and (2) at least one substance selected from the group consisting of N-[8-(2- hydroxybenzoyl) amino] capry lie acid and its pharmaceutically acceptable salts; wherein said subject had failed to respond to existing oral vitamin Bs 2 treatment.
  • Fig. 1 is a graph of serum vitamin Bi 2 concentration as a function of time.
  • SNAC means Sodium ⁇ N-saiicyioyl ⁇ 8 ⁇ aminocaprylate, Monosodium 8-(N-saIicyloylamino) octanoate, N-(salicyIoyl)-8- aminooctanoic acid monosodium salt, monosodium N- ⁇ 8-(2 phenoxybenzoyl)amino ⁇ octanoate, E414 monosodium salt or sodium 8-[(2- hydroxybenzoyl)amino]octanoate. It has the structure
  • Vitamin Bi 2 means any member of a group of cobalt- containing compounds known as cobalamins which include, but is not limited to cyanocobalamin, hydroxocobalatnin, methylcobalamin, and 5-deoxyadenosyIcobalamin.
  • treatment means any treatment of a disease or disorder in a mammal, including: preventing or protecting against the disease or disorder, that is, causing the clinical symptoms not to develop; inhibiting the disease or disorder, that is, arresting or suppressing the development of clinical symptoms; and/or relieving the disease or disorder, that is, causing the regression of clinical symptoms.
  • mammal include human subjects.
  • carrier excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent, solubilizing agent
  • excipient emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent, solubilizing agent
  • intra factor protein means is a glycoprotein produced by the parietal cells of the stomach. It is necessary for the absorption of vitamin B 12 later on in the terminal ileum.
  • the treatment is directed to subjects that had failed to respond to existing oral vitamin Bi 2 treatment.
  • tablets are used for the treatment.
  • Such tablets contain from about 0.0 lmg to about 25 mg of vitamin B 12 and from about 1 mg to about 600 mg of SNAC each, preferably from about 0.02 mg to about 25 mg of vitamin Bi 2 and more preferably from about 0.1 mg to about 20 mg of vitamin B
  • the preferred weight ratio of vitamin B 12 and SNAC in the tablet is from about 2: 1 to about 1:700, more preferably from about 1:2 to about 1 :600 or from about 1 :3 to about 1 :20 and the most preferably from about 1 :4 to about 1: 10.
  • the pharmaceutical composition is in the form of tablets.
  • each tablet contains from about 0.01 mg to about 25 mg of vitamin Bi 2 and from about 50 mg to about 600 mg of SNAC. More preferably, each tablet contains from about 0.02 mg to about 20 mg of vitamin Bi 2 . More preferably, each tablet contains from about 0.1 mg to about 10 mg of vitamin Bi 2 . The most preferably, each tablet contains about 15 to 20 mg of vitamin Bi 2 and about 50 to 100 mg of SNAC, or about 0.1 to 1.5 mg of vitamin B ⁇ 2 and about 25 to 150 mg of SNAC.
  • the tablet further contains at least one of a carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent, solubilizing agent or combinations thereof.
  • the tablet optionally contains from about
  • Capmul PG-8 1 to 25 mg of Capmul PG-8 and optionally contains from about 0.5 to 10 mg of providone.
  • Capmul PG-8 is in an amount from about 2 to 20 mg and Providone is in an amount from about 1 to 8 mg.
  • Capmul PG-8 is in an amount from about 5 to 15 mg and the Providone is in an amount from about 1.5 to 5 mg. More preferably, Capmul PG-8 is in an amount from about 5 to 10 mg and Providone is in an amount from about 1.5 to 5 mg.
  • vitamin B 12 depends on the presence of sufficient intrinsic factor protein, secreted from gastric parietal cells.
  • the average diet supplies about 10 meg/day of vitamin Bi 2 in a protein-bound form that is available for absorption after normal digestion.
  • Vitamin B 12 is bound to intrinsic factor during transit through the stomach; separation occurs in the terminal ileum, and vitamin Bj 2 enters the mucosal cell for absorption via a receptor mediated process. It is then transported by the transcobalamin binding proteins. A small amount (approximately 1% of the total amount ingested) is absorbed by simple diffusion, but this mechanism is adequate only with very large doses. It is also believed that SNAC will allow B [ 2 to bypass its usual receptor mediated process.
  • any range of numbers recited in the specification or paragraphs hereinafter describing or claiming various aspects of the invention, such as that representing a particular set of properties, units of measure, conditions, physical states or percentages, is intended to literally incorporate expressly herein by reference or otherwise, any number falling within such range, including any subset of numbers or ranges subsumed within any range so recited.
  • the preparation method for JV-[8-(2-hydroxybenzoyl) amino]caprylic acid and SNAC involves the following steps:
  • the starting material is salicylamide, which is converted to form Carsalam.
  • the second step involves the alkylation of Carsalam.
  • the penultimate step is a hydrolysis to cleave the ethyl protection group at the end of the alkyl chain and spring open the heterocyclic ring forming the free acid of SNAC.
  • the sodium salt of the SNAC free acid is formed by reaction with a 1% excess stoichiometric amount of sodium hydroxide base. Upon cooling the precipitated product is isolated by centrifugation and vacuum dried prior to packaging.
  • the in-process controls for the synthetic scheme are given in Table I.
  • Vitamin Bj 2 , SNAC, carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent, solubilizing agent are screened through a #35 sieve and transferred into a sealed containers.
  • 50 mg of Vitamin B i2 is weighed and mixed thoroughly with 11 grams of a carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent and/or solubilizing agent.
  • Vitamin Bj 2 tablets 100 vitamin Bj 2 tablets are made, with each tablet containing 0.5 mg of Vitamin B 12 and 110 mg of a carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent and/or solubilizing agent. These tablets are used as a control.
  • Vitamin B 12 1 gram of SNAC are weighed and thoroughly mixed with 10 grams of a carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent and/or solubilizing agent.
  • 100 vitamin Bi 2 tablets are made, with each tablet containing 0.5 mg of Vitamin B ⁇ .
  • the process is repeated to make tablet batches containing 1.0 mg, 0.8 mg, 0.6 mg, 0.4 mg and 0.2 of Vitamin Bj 2 , respectively.
  • These tablets have the following specifications for release of SNAC component:
  • Example 4 Male Sprague-Dawley rats (325-35Og) were dosed with vitamin B 12 intravenously (0.5 mg/kg) alone, or orally with the tablets made in Example 4 at a dose of 50 mg/kg vitamin Bi 2 alone or in combination with SNAC at 200 mg/kg. Blood samples were collected at 0, 3, 10, 20, 30, 60, 120, 240 and 360 minutes post dosing. Plasma samples were analyzed for B 12 by RIA. The model independent PK metrics obtained following B12-SNAC combination were compared to those obtained following B 12 alone. The testing results are shown in Table 1.
  • Each tablet contains the followings:
  • Treatment B a single oral dose of cyanocobalamin/SNAC (5 mg cyanocobalamin/ 100 mg SNAC) administered in the fasted state as a tablet. (6 subjects);
  • Treatment C a single oral dose of cyanocobalamin alone (5 mg cyanocobalamin, VitaLabs, commercial) administered in the fasted state as a tablet. (6 subjects).
  • Treatment D a single intravenous dose of cyanocobalamin (1 mg cyanocobalamin) administered in the fasted state. (4 subjects). Each subject received a 1 mL intravenous injection of a 1 mg/mL (1000 ⁇ g/mL) solution resulting in a total dose of 1 mg cyanocobalamin.
  • cyanocobalamin/SNAC tablets were administered in a single dose as tablets with 50 mL of plain water. Twenty-five blood samples were drawn for cyanocobalamin analyses at the following time points: within 30 minutes pre-dose and at Minutes 2, 5, 10, 20, 30, 40, 50, and at Hours 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20 and 24 post-dose.
  • Pharmacokinetic metrics was obtained following a model independent pharmacokinetic analysis of individual cyanocobalamin concentrations. Descriptive statistics was used to summarize the results.
  • B 12 peak concentration is 12847 ⁇ 6613 pg/mL and occur within 1 hour post dose (mean tmax of 0.50 ⁇ 0.21 hours).
  • Mean AUClast (0-24) value is 54618 ⁇ 16392 hr*pg/mL.
  • the percent coefficient of variation (%CV) is 51.5% for Cmax and 30.0% for AUC.
  • cyanocobalamin 1 mg cyanocobalamin administered in the fasted state (4 subjects).
  • Mean B 12 peak concentration is 221287 ⁇ 80248 pg/mL and mean AUClast (0-24) value is 215391 ⁇ 44602 hr*pg/mL.
  • the percent coefficient of variation (%CV) is 36.3% for Cmax and 20.7% for AUC.
  • the mean bioavailability of 1 tablet of 5 mg vitamin B 12 alone, 1 tablet of 5 mg vitamin B 12/100 mg SNAC, and 2 tablets of 5 mg vitamin B 12/ 100 mg SNAC are 2.15 ⁇ 0.77%, 5.07 ⁇ 1.52, and 5.92 ⁇ 3.05 %, respectively. (Note: 2 tablets of 5 mg vitamin B 12/ 100 mg SNAC were dosed previously in a pilot arm are designated Treatment A).
  • the mean tmax of 1 tablet of 5 mg vitamin B 12 alone, 1 tablet of 5 mg vitamin B 12/100 mg SNAC, and 2 tablets of 5 mg vitamin B 12/ 100 mg SNAC are 6.8 ⁇ 3.2 hours, 0.50 ⁇ 0.21 hours, and 0.54 ⁇ 0.32 hours, respectively.
  • Vitamin B 12 bioavailability was ⁇ 240 % greater for the 1 tablet of 5 mg B 12/ 100 mg SNAC compared to 5 mg B 12 commercial formulation.
  • Mean peak B 12 concentrations following B 12 commercial oral formulation occurred significantly later compared to that following the B12/SNAC combinations likely due to a different site of absorption between the two oral formulations. This is consistent with literature data describing intestinal absorption of B 12 occurring in the distal section of the gastrointestinal tract in the absence of the carder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method and composition for treating vitamin B12 deficiency in mammals that fail to respond to oral vitamin B12 therapy, including preparing a pharmaceutical composition for oral administration containing vitamin B12 and at least one substance selected from the group consisting of N-[8-(2-hydroxybenzoyl) amιno]caprylιc acid and its pharmaceutically acceptable salts, then administering the pharmaceutical composition to a subject to effectively treat the vitamin B12 deficiency.

Description

Method of Treating Vitamin B 12 Deficiency
FIELD OF THE INVENTION
[0001] The present invention relates generally to methods of treating vitamin B12 deficiency and pharmaceutical compositions for such treatment.
BACKGROUND OF THE INVENTION
[0002] Vitamin B12 is important for the normal functioning of the brain and nervous system and for the formation of blood. It is involved in the metabolism of every cell of the body, especially affecting the DNA synthesis and regulation but also fatty acid synthesis and energy production. Its effects are still not completely known. [0003] Cyanocobalamin is the most stable and widely used form of vitamin Bu¬ ll is bound to plasma proteins and stored in the liver. Vitamin Bi2 is excreted in the bile and undergoes some enterohepatic recycling. Absorbed vitamin Bi2 is transported via specific Bj2 binding proteins, transcobalamin I and II, to the various tissues. The liver is the main organ for vitamin B 12 storage.
[0004] Vitamin B]2 deficiency can potentially cause severe and irreversible damage, especially to the brain and nervous system. Oral tablets containing vitamin Bi2 have been developed to treat vitamin Bj2 deficiency. However, many patients with vitamin B n deficiency do not respond to oral vitamin B12 treatment. There is a need to develop a treatment for these patients.
BRIEF SUMMARY OF THE INVENTION
[0010] One aspect of the invention is directed to a method for treating vitamin B [2 deficiency in a subject, comprising the steps of (a) preparing a pharmaceutical composition for oral administration containing (1) vitamin B]2 and (2) at least one substance selected from the group consisting of /V-[8-(2~hydroxybenzoyl) amino]caprylic acid and its pharmaceutically acceptable salts; and (b) administering the pharmaceutical composition to the subject to effectively treat said vitamin Bi2 deficiency.
[0011] Another aspect of the invention is directed to a pharmaceutical composition for treating vitamin Bj2 deficiency in a subject, comprising (1) vitamin B12 and (2) at least one substance selected from the group consisting of N-[8-(2- hydroxybenzoyl) amino] capry lie acid and its pharmaceutically acceptable salts; wherein said subject had failed to respond to existing oral vitamin Bs2 treatment.
[0012] The contents of the patents and publications cited herein and the contents of these documents cited in these patents and publications are hereby incorporated herein by reference to the extent permitted.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013 ] Fig. 1 is a graph of serum vitamin Bi2 concentration as a function of time.
DETAILED DESCRIPTION
[0014] As used herein, the term "SNAC" means Sodium~N-saiicyioyl~8~ aminocaprylate, Monosodium 8-(N-saIicyloylamino) octanoate, N-(salicyIoyl)-8- aminooctanoic acid monosodium salt, monosodium N- { 8-(2 phenoxybenzoyl)amino} octanoate, E414 monosodium salt or sodium 8-[(2- hydroxybenzoyl)amino]octanoate. It has the structure
Figure imgf000005_0001
'W-[8-(2-hydroxybenzoyl) amino]caprylic acid " has an empirical formula C1SH2INO4.
[0015] The term "Vitamin Bi2" means any member of a group of cobalt- containing compounds known as cobalamins which include, but is not limited to cyanocobalamin, hydroxocobalatnin, methylcobalamin, and 5-deoxyadenosyIcobalamin.
[0016] The term "treatment" or "treating" means any treatment of a disease or disorder in a mammal, including: preventing or protecting against the disease or disorder, that is, causing the clinical symptoms not to develop; inhibiting the disease or disorder, that is, arresting or suppressing the development of clinical symptoms; and/or relieving the disease or disorder, that is, causing the regression of clinical symptoms. The term "mammal" include human subjects.
[0017 ] The terms "carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent, solubilizing agent" are as defined in the Handbook of Pharmaceutical Excipients (fourth edition) by Raymond C. Rowe, Paul J. Sheskey and Paul J. Weller, the content of which is herein incorporated by reference. [0018 ] The term "intrinsic factor protein" means is a glycoprotein produced by the parietal cells of the stomach. It is necessary for the absorption of vitamin B12 later on in the terminal ileum.
[0019] In a preferred embodiment, the treatment is directed to subjects that had failed to respond to existing oral vitamin Bi2 treatment. Preferably, tablets are used for the treatment. Such tablets contain from about 0.0 lmg to about 25 mg of vitamin B12 and from about 1 mg to about 600 mg of SNAC each, preferably from about 0.02 mg to about 25 mg of vitamin Bi2 and more preferably from about 0.1 mg to about 20 mg of vitamin B|2 and the most preferably from about 0.5 mg to 10 mg of vitamin Bj2 and from about 10 mg to about 200 mg of SNAC in each tablet.
[0020] The preferred weight ratio of vitamin B12 and SNAC in the tablet is from about 2: 1 to about 1:700, more preferably from about 1:2 to about 1 :600 or from about 1 :3 to about 1 :20 and the most preferably from about 1 :4 to about 1: 10.
[0021] In a preferred embodiment, the pharmaceutical composition is in the form of tablets. Preferrably, each tablet contains from about 0.01 mg to about 25 mg of vitamin Bi2 and from about 50 mg to about 600 mg of SNAC. More preferably, each tablet contains from about 0.02 mg to about 20 mg of vitamin Bi2. More preferably, each tablet contains from about 0.1 mg to about 10 mg of vitamin Bi2. The most preferably, each tablet contains about 15 to 20 mg of vitamin Bi2 and about 50 to 100 mg of SNAC, or about 0.1 to 1.5 mg of vitamin B^2 and about 25 to 150 mg of SNAC.
[0022] In another preferred embodiment, the tablet further contains at least one of a carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent, solubilizing agent or combinations thereof.
[0023 ] In another preferred embodiment, the tablet optionally contains from about
1 to 25 mg of Capmul PG-8 and optionally contains from about 0.5 to 10 mg of providone. Preferably, Capmul PG-8 is in an amount from about 2 to 20 mg and Providone is in an amount from about 1 to 8 mg. Preferably, Capmul PG-8 is in an amount from about 5 to 15 mg and the Providone is in an amount from about 1.5 to 5 mg. More preferably, Capmul PG-8 is in an amount from about 5 to 10 mg and Providone is in an amount from about 1.5 to 5 mg.
[0024] Without intending to be bound by any particular theory of operation, it is believed that gastrointestinal absorption of vitamin B 12 depends on the presence of sufficient intrinsic factor protein, secreted from gastric parietal cells. The average diet supplies about 10 meg/day of vitamin Bi2 in a protein-bound form that is available for absorption after normal digestion. Vitamin B 12 is bound to intrinsic factor during transit through the stomach; separation occurs in the terminal ileum, and vitamin Bj2 enters the mucosal cell for absorption via a receptor mediated process. It is then transported by the transcobalamin binding proteins. A small amount (approximately 1% of the total amount ingested) is absorbed by simple diffusion, but this mechanism is adequate only with very large doses. It is also believed that SNAC will allow B [2 to bypass its usual receptor mediated process.
[0025] The following examples are given as specific illustrations of the invention.
It should be understood, however, that the invention is not limited to the specific details set forth in the examples. All parts and percentages in the examples, as well as in the remainder of the specification, are by weight unless otherwise specified.
[0026] Further, any range of numbers recited in the specification or paragraphs hereinafter describing or claiming various aspects of the invention, such as that representing a particular set of properties, units of measure, conditions, physical states or percentages, is intended to literally incorporate expressly herein by reference or otherwise, any number falling within such range, including any subset of numbers or ranges subsumed within any range so recited. The term "about" when used as a modifier for, or in conjunction with, a variable, is intended to convey that the numbers and ranges disclosed herein are flexible and that practice of the present invention by those skilled in the art using concentrations, amounts, contents, carbon numbers, and properties that are outside of the range or different from a single value, will achieve the desired result, namely, effective treatment of a subject with vitamin B12 deficiency which failed to respond to existing oral vitamin Bi2 tablets as well as pharmaceutical compositions for such treatment.
Example 1. Preparation of iV-[8-(2-hydroxybenzoyl) amino]caprylic acid and SNAC
[0027] The preparation method for JV-[8-(2-hydroxybenzoyl) amino]caprylic acid and SNAC involves the following steps: The starting material is salicylamide, which is converted to form Carsalam. The second step involves the alkylation of Carsalam. The penultimate step is a hydrolysis to cleave the ethyl protection group at the end of the alkyl chain and spring open the heterocyclic ring forming the free acid of SNAC. In the final step, the sodium salt of the SNAC free acid is formed by reaction with a 1% excess stoichiometric amount of sodium hydroxide base. Upon cooling the precipitated product is isolated by centrifugation and vacuum dried prior to packaging. The in-process controls for the synthetic scheme are given in Table I.
Table I. In-process controls for SNAC Manufacturing Process.
Figure imgf000008_0001
Example 2. Preparation of vitamin Bn tablets.
[0028] The tablet die and punches are checked to ensure that they are clean and that their surfaces are dusted with magnesium stearate powder. Vitamin Bj2, SNAC, carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent, solubilizing agent are screened through a #35 sieve and transferred into a sealed containers. 50 mg of Vitamin Bi2 is weighed and mixed thoroughly with 11 grams of a carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent and/or solubilizing agent. 100 vitamin Bj2 tablets are made, with each tablet containing 0.5 mg of Vitamin B12 and 110 mg of a carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent and/or solubilizing agent. These tablets are used as a control.
Example 3. Preparation of Vitamin B 12 and SNAC tablets
[0029J 50 mg of Vitamin B12, 1 gram of SNAC are weighed and thoroughly mixed with 10 grams of a carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent and/or solubilizing agent. 100 vitamin Bi2 tablets are made, with each tablet containing 0.5 mg of Vitamin B^. 10 mg of SNAC and 100 mg of a carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent and/or solubilizing agent. The process is repeated to make tablet batches containing 1.0 mg, 0.8 mg, 0.6 mg, 0.4 mg and 0.2 of Vitamin Bj2, respectively. These tablets have the following specifications for release of SNAC component:
Figure imgf000009_0001
Example 4, Preparation of Tablets for Testing on Rats
[0030] Tablets with four types of different ingredients were made as follows:
(1) 8.8 mg of vitamin Bi2, 35 mg of SNAC were weighed, thoroughly mixed and made into a tablet for dosing on rat; (2) 8.8 mg of vitamin Bi2, 35 mg of SNAC and 5 mg of Capmul PG-8 were weighed, thoroughly mixed and made into a tablet; (3) 8.8 mg of vitamin Bi2, 35 mg of SNAC and 0.9 mg of Providone were weighed, thoroughly mixed and made into a tablet. Each of the four proceeses was repeated to produce more tablets.
Example 5. Dosing Sprague-Dawley Rats
[0031] Male Sprague-Dawley rats (325-35Og) were dosed with vitamin B 12 intravenously (0.5 mg/kg) alone, or orally with the tablets made in Example 4 at a dose of 50 mg/kg vitamin Bi2 alone or in combination with SNAC at 200 mg/kg. Blood samples were collected at 0, 3, 10, 20, 30, 60, 120, 240 and 360 minutes post dosing. Plasma samples were analyzed for B 12 by RIA. The model independent PK metrics obtained following B12-SNAC combination were compared to those obtained following B 12 alone. The testing results are shown in Table 1.
Table 1. Comparative Testing Results for Vitamin B 12 Absorption
Cmax Tmax AUC Mean
Group (N=5) (ug/mL) (min) (ug*min/mL) Bioavailability
Mean S. D Mean S.D Mean S.D %
0.5mg/kg Vitamin B12 (IV) 2.15 0.64 4.4 3.13 65.84 11
50mg/kg Vitamin B12 atone (PO) 0.14 0.07 52 17.9 28.72 13 0.42
50mg/kg Vitamin BJJ + 200mg/kg
7.99 2.41 24 5.48 522 37 179 7 93 SNAC (PO)
Example 6. Preparation of Tablets for Testing on Human Subjects
[0032] Tablets were made from Cyanocobalamin, SNAC, Kollidon 9OF,
Anhydrous Emcompress USP/EP and Magnesium Stearate, NF/BP/EP/JP. Each tablet contains the followings:
Figure imgf000011_0001
Example 7. Dosing Human Subjects
[0033] Sixteen healthy male subjects were randomized to receive one of the following treatments:
(1) Treatment B: a single oral dose of cyanocobalamin/SNAC (5 mg cyanocobalamin/ 100 mg SNAC) administered in the fasted state as a tablet. (6 subjects);
(2) Treatment C: a single oral dose of cyanocobalamin alone (5 mg cyanocobalamin, VitaLabs, commercial) administered in the fasted state as a tablet. (6 subjects).
(3) Treatment D: a single intravenous dose of cyanocobalamin (1 mg cyanocobalamin) administered in the fasted state. (4 subjects). Each subject received a 1 mL intravenous injection of a 1 mg/mL (1000 μg/mL) solution resulting in a total dose of 1 mg cyanocobalamin.
The subjects were fasted overnight prior to dosing and had no liquids (including water) consumption for at least one hour before and after dosing. The oral forms of cyanocobalamin/SNAC tablets were administered in a single dose as tablets with 50 mL of plain water. Twenty-five blood samples were drawn for cyanocobalamin analyses at the following time points: within 30 minutes pre-dose and at Minutes 2, 5, 10, 20, 30, 40, 50, and at Hours 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 20 and 24 post-dose.
Pharmacokinetic metrics was obtained following a model independent pharmacokinetic analysis of individual cyanocobalamin concentrations. Descriptive statistics was used to summarize the results.
Following 1 tablet of 5 mg B 12/ 100 mg SNAC mean B 12 peak concentration is 12847 ± 6613 pg/mL and occur within 1 hour post dose (mean tmax of 0.50 ± 0.21 hours). Mean AUClast (0-24) value is 54618 ± 16392 hr*pg/mL. The percent coefficient of variation (%CV) is 51.5% for Cmax and 30.0% for AUC.
Following a single oral dose of cyanocobalamin alone (5 mg cyanocobalamin, VitaLabs, commercial) mean B12 peak concentration is 1239 ± 450 pg/mL and occur between 3 to 10 hours post-dose (mean tmax of 6.8 ± 3.2 hours). Mean AUClast (0-24) value is 23131 ± 8343 hr*pg/mL. The percent coefficient of variation (%CV) is 36.3% for Cmax and 36.1% for AUC.
Following a single intravenous dose of cyanocobalamin ( 1 mg cyanocobalamin) administered in the fasted state (4 subjects). Mean B 12 peak concentration is 221287 ± 80248 pg/mL and mean AUClast (0-24) value is 215391 ± 44602 hr*pg/mL. The percent coefficient of variation (%CV) is 36.3% for Cmax and 20.7% for AUC.
The mean bioavailability of 1 tablet of 5 mg vitamin B 12 alone, 1 tablet of 5 mg vitamin B 12/100 mg SNAC, and 2 tablets of 5 mg vitamin B 12/ 100 mg SNAC are 2.15 ± 0.77%, 5.07 ± 1.52, and 5.92 ± 3.05 %, respectively. (Note: 2 tablets of 5 mg vitamin B 12/ 100 mg SNAC were dosed previously in a pilot arm are designated Treatment A).
The mean tmax of 1 tablet of 5 mg vitamin B 12 alone, 1 tablet of 5 mg vitamin B 12/100 mg SNAC, and 2 tablets of 5 mg vitamin B 12/ 100 mg SNAC are 6.8 ± 3.2 hours, 0.50 ± 0.21 hours, and 0.54 ± 0.32 hours, respectively.
No adverse events were observed during the given treatments. All formulations appear to be safe and well tolerated.
It was found surprisingly that the extent of B 12 absoiption, measured as Cmax and AUC, was significantly enhanced by the administration of the cyanocobalamin/SNAC combination. Vitamin B 12 bioavailability was ~240 % greater for the 1 tablet of 5 mg B 12/ 100 mg SNAC compared to 5 mg B 12 commercial formulation. Mean peak B 12 concentrations following B 12 commercial oral formulation occurred significantly later compared to that following the B12/SNAC combinations likely due to a different site of absorption between the two oral formulations. This is consistent with literature data describing intestinal absorption of B 12 occurring in the distal section of the gastrointestinal tract in the absence of the carder.
[0034] The principles, preferred embodiments, and modes of operation of the present invention have been described in the foregoing specification. The invention which is intended to be protected herein, however, is not to be construed as limited to the particular forms disclosed, since these are to be regarded as illustrative rather than restrictive. Variations and changes may be made by those skilled in the art, without departing from the spirit of the invention.

Claims

What is claimed is:
1. A method for treating vitamin Bi2 deficiency in a subject, comprising the steps of
(a) preparing a pharmaceutical composition for oral administration containing (1) vitamin B12 and (2) at least one substance selected from the group consisting of /V-[8-(2-hydroxybenzoyl) aminojcaprylic acid and its pharmaceutically acceptable salts; and
(b) administering said pharmaceutical composition to said subject to effectively treat said vitamin Bn deficiency.
2. The method of claim 1, wherein said subject had failed to respond to existing oral vitamin Bi2 treatment.
3. The method of claim 1, wherein said pharmaceutical composition comprises a tablet.
4. The method of claim 3, wherein said tablet comprises from about O.Olmg to about 25 mg of vitamin B 12 and from about 1 mg to about 600 mg of SNAC.
5. The method of claim 3, wherein said tablet comprises from about 0.02 mg to about 25 mg of vitamin Bi2.
6. The method of claim 3, wherein said tablet comprises from about 0.1 mg to about 20 mg of vitamin Bi2.
7. The method of claim 3, wherein said tablet comprises about 0.5 mg of vitamin B!2 and about 17.5 mg of SNAC.
8. The method of claim 1, wherein said pharmaceutical composition has a weight ratio of vitamin Bi2 and SNAC from about 2: 1 to about 1 :700.
9. The method of claim 8, wherein said weight ratio is from about 1 :2 to about 1 :600.
10. The method of claim 8, wherein said weight ratio is from about 1 :3 to about 1 :20.
11. The method of claim 8, wherein said weight ratio is about 1 :4.
12. The method of claim 8, wherein said weight ratio is from about 1 :500 to about 1:700.
13. The method of claim 3, wherein said pharmaceutical composition further comprises at least one of a carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent, solubilizing agent or combinations thereof.
14. A pharmaceutical composition for treating vitamin B12 deficiency in a subject, comprising (1) vitamin B 12 and (2) at least one substance selected from the group consisting of iV-[8-(2-hydiOxybenzoyl) amino]caprylic acid and its pharmaceutically acceptable salts; wherein said subject had failed to respond to oral vitamin B[2 treatment.
15. The pharmaceutical composition of claim 14, wherein said pharmaceutical composition comprises a tablet.
16. The pharmaceutical composition of claim 15, wherein said tablet comprises from about 0.01 mg to about 25 mg of vitamin B 12 and from about 50 mg to about 600 mg of SNAC.
17. The pharmaceutical composition of claim 15, wherein said tablet comprises from about 0.02 mg to about 20 mg of vitamin B12.
18. The pharmaceutical composition of claim 15, wherein said tablet comprises from about 0.1 mg to about 10 mg of vitamin Bi2.
19. The pharmaceutical composition of claim 15, wherein said tablet comprises about 1 to 15 mg of vitamin Bi2 and about 50 to 200 mg of SNAC.
20. The pharmaceutical composition of claim 14, further comprising at least one of a carrier, excipient, emulsifier, stabilizer, sweetener, flavoring agent, diluent, coloring agent, solubilizing agent or combinations thereof.
PCT/US2008/082064 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency WO2009059188A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP2010532292A JP5555634B2 (en) 2007-11-02 2008-10-31 Method for treating vitamin B12 deficiency
PL08844673T PL2215047T3 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency
AU2008318423A AU2008318423B2 (en) 2007-11-02 2008-10-31 Method of treating vitamin B12 deficiency
NZ585080A NZ585080A (en) 2007-11-02 2008-10-31 Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency
EP08844673.7A EP2215047B1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency
BRPI0817396A BRPI0817396C8 (en) 2007-11-02 2008-10-31 pharmaceutical composition to treat vitamin B deficiência² deficiency
CA2704780A CA2704780C (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency
DK08844673.7T DK2215047T3 (en) 2007-11-02 2008-10-31 METHOD OF TREATING VITAMIN B12 LACK
MX2010004716A MX2010004716A (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency.
RU2010118423/15A RU2469728C2 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 insufficiency
ES08844673.7T ES2443817T3 (en) 2007-11-02 2008-10-31 Method to treat vitamin B12 deficiency
CN200880119724.0A CN101952241B (en) 2007-11-02 2008-10-31 Method of treating vitamin B12 deficiency
CL2010000434A CL2010000434A1 (en) 2007-11-02 2010-04-30 Use of a pharmaceutical composition comprising vitamin b12 and n- (8- (2-hydroxybenzoyl) animo) caprylic acid or its salts to prepare a medicament useful in the treatment of vitamin b12 deficiency; pharmaceutical composition.
HK11100634.9A HK1146480A1 (en) 2007-11-02 2011-01-21 Method of treating vitamin b12 deficiency b12

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US98489807P 2007-11-02 2007-11-02
US60/984,898 2007-11-02
US2010808P 2008-01-09 2008-01-09
US61/020,108 2008-01-09
US8356608P 2008-07-25 2008-07-25
US61/083,566 2008-07-25

Publications (1)

Publication Number Publication Date
WO2009059188A1 true WO2009059188A1 (en) 2009-05-07

Family

ID=40591491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/082064 WO2009059188A1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency

Country Status (19)

Country Link
US (3) US8022048B2 (en)
EP (1) EP2215047B1 (en)
JP (1) JP5555634B2 (en)
KR (1) KR101344369B1 (en)
CN (1) CN101952241B (en)
AU (1) AU2008318423B2 (en)
BR (1) BRPI0817396C8 (en)
CA (1) CA2704780C (en)
CL (1) CL2010000434A1 (en)
CO (1) CO6280475A2 (en)
DK (1) DK2215047T3 (en)
ES (1) ES2443817T3 (en)
HK (1) HK1146480A1 (en)
MX (1) MX2010004716A (en)
NZ (1) NZ585080A (en)
PL (1) PL2215047T3 (en)
PT (1) PT2215047E (en)
RU (1) RU2469728C2 (en)
WO (1) WO2009059188A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501062A (en) * 2009-08-03 2013-01-10 エミスフィアー テクノロジーズ インコーポレイテッド Rapid-acting naproxen composition with reduced gastrointestinal effects
US20160074420A1 (en) * 2010-02-24 2016-03-17 Emisphere Technologies, Inc. Oral b12 therapy
EP2827845B1 (en) 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US10960052B2 (en) 2010-12-16 2021-03-30 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid
US11033499B2 (en) 2012-06-20 2021-06-15 Novo Nordisk A/S Tablet formulation comprising a GLP-1 peptide and a delivery agent
US11034746B2 (en) 2011-04-12 2021-06-15 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US11123296B2 (en) 2012-03-22 2021-09-21 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
US11833248B2 (en) 2018-02-02 2023-12-05 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8805208B2 (en) * 2012-02-03 2014-08-12 Tyco Electronics Subsea Communications Llc System and method for polarization de-multiplexing in a coherent optical receiver
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
EP3445356B1 (en) 2016-04-22 2021-06-30 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (en) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. QUICKLY PRODUCTIVE PLANT MEDICINES AND BIOLOGICALLY ACTIVE ADDITIVES
AR113750A1 (en) * 2017-10-05 2020-06-10 Receptor Holdings Inc HERBAL COMPOSITIONS WITH BETTER BIODAVAILABILITY
WO2019071213A1 (en) * 2017-10-05 2019-04-11 Receptor Life Sciences, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US20050186267A1 (en) * 2002-09-13 2005-08-25 Thompson Diane O. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US20060024241A1 (en) 2004-08-02 2006-02-02 Bebaas, Inc. Vitamin B12 compositions
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2266412A1 (en) * 1996-09-18 1998-03-26 William J. Sarill Compositions containing cobalamin and amino acids
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6255294B1 (en) 1998-12-28 2001-07-03 Allergy Limited Cyanocobalamin (vitamin B12) treatment in allergic disease
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
ATE554062T1 (en) 2000-03-21 2012-05-15 Emisphere Tech Inc METHOD FOR PRODUCING ALKYLATED SALICYLAMEDES BY A DICARBOXYLATE INTERMEDIATE
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
PT1397156E (en) 2001-06-01 2007-05-31 Novartis Ag Oral administration of parathyroid hormone and calcitonin
MXPA04001418A (en) 2001-08-17 2004-05-27 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments.
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
PE20040724A1 (en) 2002-08-01 2004-12-06 Novartis Ag COMPOSITION FOR THE ORAL ADMINISTRATION OF CALCITONIN
EP1611084A1 (en) 2003-04-04 2006-01-04 DSM IP Assets B.V. Process for the manufacture of n-alkoxalyl-alaninates
US6938439B2 (en) 2003-05-22 2005-09-06 Cool Clean Technologies, Inc. System for use of land fills and recyclable materials
JP3924616B2 (en) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 Temperature measurement method using minute size temperature sensing element
CA2531136A1 (en) 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
MXPA06000446A (en) 2003-07-11 2006-04-07 Novartis Ag Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form.
WO2005014031A1 (en) 2003-07-23 2005-02-17 Novartis Ag Use of calcitonin in osteoarthritis
CA2897225C (en) * 2004-05-06 2017-12-05 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
AU2006312117A1 (en) 2005-11-04 2007-05-18 Genta Incorporated Pharmaceutical gallium compositions and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US20050186267A1 (en) * 2002-09-13 2005-08-25 Thompson Diane O. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US20060024241A1 (en) 2004-08-02 2006-02-02 Bebaas, Inc. Vitamin B12 compositions
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARBIT EHUD ET AL., THROMBOSIS JOURNAL, BIOMED CENTRAL, LONDON, vol. 4, no. 1, 10 May 2006 (2006-05-10), pages 6
MAJURU, S, DRUG DELIVERY TECHNOLOGY, vol. 4, no. 8, 1 January 2004 (2004-01-01), pages 85 - 89
MALKOV DMITRY ET AL., CURRENT DRUG DELIVERY, vol. 2, 2 April 2005 (2005-04-02), pages 191 - 197
QI RIONG ET AL.: "DATABASE BIOSIS", December 2003, BIOSCIENCES INFORMATION SERVICE
RAYMOND C. ROWE; PAUL J. SHESKEY; PAUL J. WELLER: "Handbook of Pharmaceutical Excipients"
See also references of EP2215047A4

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501062A (en) * 2009-08-03 2013-01-10 エミスフィアー テクノロジーズ インコーポレイテッド Rapid-acting naproxen composition with reduced gastrointestinal effects
US20160074420A1 (en) * 2010-02-24 2016-03-17 Emisphere Technologies, Inc. Oral b12 therapy
US10960052B2 (en) 2010-12-16 2021-03-30 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid
US11382957B2 (en) 2010-12-16 2022-07-12 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
US11034746B2 (en) 2011-04-12 2021-06-15 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US11117947B2 (en) 2011-04-12 2021-09-14 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US11123296B2 (en) 2012-03-22 2021-09-21 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
EP2827845B1 (en) 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
US11759501B2 (en) 2012-03-22 2023-09-19 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US11759503B2 (en) 2012-03-22 2023-09-19 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US11759502B2 (en) 2012-03-22 2023-09-19 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US11033499B2 (en) 2012-06-20 2021-06-15 Novo Nordisk A/S Tablet formulation comprising a GLP-1 peptide and a delivery agent
US11833248B2 (en) 2018-02-02 2023-12-05 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Also Published As

Publication number Publication date
CN101952241A (en) 2011-01-19
US20100016255A1 (en) 2010-01-21
HK1146480A1 (en) 2011-06-10
RU2469728C2 (en) 2012-12-20
JP5555634B2 (en) 2014-07-23
PL2215047T3 (en) 2014-05-30
CA2704780A1 (en) 2009-05-07
RU2010118423A (en) 2011-12-10
EP2215047A1 (en) 2010-08-11
KR20100126263A (en) 2010-12-01
JP2011502997A (en) 2011-01-27
MX2010004716A (en) 2010-12-17
AU2008318423A1 (en) 2009-05-07
BRPI0817396C1 (en) 2020-11-17
BRPI0817396C8 (en) 2021-05-25
EP2215047A4 (en) 2010-11-10
NZ585080A (en) 2012-05-25
CO6280475A2 (en) 2011-05-20
AU2008318423B2 (en) 2013-12-05
DK2215047T3 (en) 2014-02-03
US8022048B2 (en) 2011-09-20
KR101344369B1 (en) 2013-12-24
EP2215047B1 (en) 2013-11-20
US20130040910A1 (en) 2013-02-14
BRPI0817396A2 (en) 2015-04-07
US20110293589A1 (en) 2011-12-01
CL2010000434A1 (en) 2011-01-28
CA2704780C (en) 2014-06-10
ES2443817T3 (en) 2014-02-20
PT2215047E (en) 2014-01-20
CN101952241B (en) 2014-06-11
BRPI0817396B8 (en) 2020-02-04
US8557792B2 (en) 2013-10-15
US8288360B2 (en) 2012-10-16
BRPI0817396B1 (en) 2019-04-24

Similar Documents

Publication Publication Date Title
AU2008318423B2 (en) Method of treating vitamin B12 deficiency
ES2950337T3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
EP2421525B1 (en) Diclofenac formulation
TW201040165A (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20240299364A1 (en) Magnesium biotinate compositions and methods of use
US20200206247A1 (en) Oral b12 therapy
EP2493484A2 (en) Gastroretentive oral high dose zinc preparations
JP2022537106A (en) Pharmaceutical dosage form containing metformin and calcium citrate
AU2019377074A1 (en) Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880119724.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08844673

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008318423

Country of ref document: AU

Ref document number: MX/A/2010/004716

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2704780

Country of ref document: CA

Ref document number: 2010532292

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 585080

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107010771

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3515/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008318423

Country of ref document: AU

Date of ref document: 20081031

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008844673

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010118423

Country of ref document: RU

Ref document number: 10066425

Country of ref document: CO

ENP Entry into the national phase

Ref document number: PI0817396

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100503